Monitor Q1 2027 for initial acute safety data from the VY1706 Alzheimer's trial, which is the stated catalyst for the CEO transition. The succession plan suggests management continuity but the stock will likely trade on pipeline data, not this organizational change.
Price Chart
Executive Summary
Voyager Therapeutics promoted Robin Swartz from COO/CBO to President, effective October 20, 2026, with a plan for her to succeed current CEO Alfred Sandrock as CEO in Q1 2027 after receipt of initial acute safety data from the VY1706 Alzheimer's trial. The filing includes a new employment agreement with a $625,000 base salary, 50% target bonus, and substantial equity grants (option for 318,500 shares and 68,250 RSUs). This is a routine executive succession and compensation arrangement with no financial results or material business changes.
Key Facts
- Robin Swartz appointed President effective October 20, 2026, and expected to succeed CEO Alfred Sandrock in Q1 2027 after VY1706 safety data readout.
- New employment agreement provides $625,000 annual base salary and 50% target bonus.
- Equity grants: option to purchase 318,500 shares (4-year monthly vest) and 68,250 RSUs (3-year annual vest), effective November 1, 2026.
- Severance includes 12 months base salary, pro-rata bonus, and COBRA for 12 months; full equity acceleration if terminated within 12 months of a sale event.
- Dr. Sandrock expected to remain on the board after succession.
Financial Impact
No financial data reported; executive compensation terms disclosed with $625,000 base salary and equity grants of 318,500 options + 68,250 RSUs.
Risk Factors
- CEO transition is contingent on VY1706 safety data — adverse results could delay or alter the succession plan.
- No financial performance data in this filing; fundamental business risk unchanged.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-427224 |
| Document: d157795d8k.htm | 0001193125-26-427224 |
| Document: 0001193125-26-427224-index-headers.html | 0001193125-26-427224 |
| Document: 0001193125-26-427224-index.html | 0001193125-26-427224 |
| Document: 0001193125-26-427224.txt | 0001193125-26-427224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.02 | awaiting T+60 | — | $1.79 (−11.39%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.79 (−44.75%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.79 (−52.77%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.79 (−56.87%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.79 (−55.80%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.79 (−52.52%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.79 (−56.76%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.79 (+52.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers